[Form 4] HeartBeam, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Marga Ortigas-Wedekind, a director of HeartBeam, Inc. (BEAT), reported multiple transactions on this Form 4. The filing shows a disposition of 112,293 shares of common stock and remaining beneficial ownership entries including 16,824 shares held indirectly. The reporting person received 60,483 restricted stock units (RSUs) granted on July 11, 2025; those RSUs vest 100% on the earlier of July 11, 2026 or the company’s 2026 annual meeting, subject to continued service as an Outside Director. The filing also discloses a stock option covering 39,394 underlying shares with an exercise price of $1.65 and an indicated post-transaction derivative beneficial ownership total of 83,029 shares. The RSUs are non-expiring (vest or cancel) and the option vesting schedule references a July 1, 2025 commencement with staged vesting.

Positive

• 60,483 RSUs granted on 07/11/2025 with 100% vesting by 07/11/2026 (or 2026 annual meeting)
• 39,394-share option issued at an exercise price of $1.65, providing potential future alignment with shareholders

Negative

• Disposition of 112,293 shares was reported, reducing direct beneficial ownership
• Significant insider sale disclosed without a reported sale price in this Form 4

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ortigas-Wedekind Marga

(Last) (First) (Middle)

2118 WALSH AVE, SUITE 210

(Street)

SANTA CLARA CA 95050

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
HeartBeam, Inc. [ BEAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								16,824	I	See Footnote
Common Stock								112,293	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Award	$0							(1)	(2)	Common Stock	60,483		60,483	D
Common Stock (right to buy)	$1.65							(3)	07/01/2035	Common Stock	39,394		83,029	D

Explanation of Responses:

1. These securities are restricted stock units (RSUs) granted on July 11, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. 100% of the RSUs shall vest on the earlier of July 11, 2026, or the date of the Issuer's 2026 annual meeting of stockholders, subject to the Reporting Person continuing to be an Outside Director (as defined in the Issuer's 2022 Equity Inventive Plan) through the applicable vesting date.

2. RSUs do not expire, they either vest or are canceled prior to vesting date

3. Granted options on September 30, 2025, one half of the total number of Shares subject to the Special Option shall vest on the three-month anniversary of the vesting commencement date (July 1, 2025) and the remaining Shares shall vest on the six-month anniversary of the vesting commencement date. These options have been issued from the Company's 2022 Equity Incentive Plan.

Remarks:

	/s/ Marga Ortigas-Wedekind	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider activity did HeartBeam (BEAT) report on this Form 4?

The director Marga Ortigas-Wedekind reported a disposition of 112,293 shares, receipt of 60,483 RSUs on 07/11/2025, and a stock option covering 39,394 underlying shares at $1.65.

When do the RSUs reported for BEAT vest?

The RSUs vest 100% on the earlier of July 11, 2026 or the company’s 2026 annual meeting, subject to continued service as an Outside Director.

What is the exercise price and size of the option disclosed?

The option covers 39,394 underlying shares with an exercise price of $1.65 and includes staged vesting tied to a 07/01/2025 vesting commencement date.

Do the RSUs expire?

No; the filing states RSUs do not expire—they either vest or are canceled prior to the vesting date.

How much common stock does the reporting person beneficially own after the transactions?

The filing shows derivative-related beneficial ownership of 83,029 shares and an indirect holding of 16,824 shares; the filing also reports a 112,293-share disposition.